Provectus Biopharmaceuticals (OTCQB: PVCT) announced results from a preclinical study of oral PV-10 in a bladder cancer model.
The study used immunologically humanized mice and was conducted by Translational Drug Development.
Oral PV-10 monotherapy scored 9.24 out of 10 in a multi-domain evaluation.
Two treated mice showed no gross bladder tumor at study end.
The company's stock rose nearly 7% over the past week.
Provectus now seeks FDA acceptance of an expanded IND for human testing.
